Mitigating Tumor Recurrence through Mitochondrial Metabolism Inhibition: A Novel NIR Laser-Induced Therapeutic Strategy
Abstract Tumor recurrence driven by mitochondrial hypermetabolism remains a critical challenge in cancer therapy, as aberrant energy metabolism fuels therapeutic resistance and disease progression. We aimed to develop a multifunctional nanoplatform combining mitochondrial metabolism inhibition, phot...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | Biological Procedures Online |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12575-025-00283-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849238781682515968 |
|---|---|
| author | Yao Liu Zujun Que Tianqi An Zhipeng Zhang Jianhui Tian |
| author_facet | Yao Liu Zujun Que Tianqi An Zhipeng Zhang Jianhui Tian |
| author_sort | Yao Liu |
| collection | DOAJ |
| description | Abstract Tumor recurrence driven by mitochondrial hypermetabolism remains a critical challenge in cancer therapy, as aberrant energy metabolism fuels therapeutic resistance and disease progression. We aimed to develop a multifunctional nanoplatform combining mitochondrial metabolism inhibition, photothermal therapy, and controlled chemotherapy to overcome tumor recurrence mechanisms. Biodegradable polydopamine nanoparticles (PDA-DOX-CO NPs) were engineered via molecular self-assembly, co-loading doxorubicin (DOX) and a carbon monoxide (CO) prodrug. The PDA-DOX-CO NPs demonstrated three synergistic therapeutic effects: (1) Photothermal ablation (48.38 °C tumor hyperthermia), (2) CO-mediated mitochondrial suppression, and (3) Spatiotemporally controlled DOX release. In HCT-116 tumor models, PDA-DOX-CO NPs with NIR irradiation induced 60% tumor complete ablation. Histopathological analysis confirmed significant apoptosis induction and mitochondrial morphology alterations in treated tumors. This “metabolic blockade + energy depletion + precision delivery” paradigm provides a synergistic solution to tumor recurrence, demonstrating enhanced therapeutic efficacy and biosafety through mitochondrial-targeted multimodal action. |
| format | Article |
| id | doaj-art-a0bc8cadbcc34772a129ecacdf69b6ae |
| institution | Kabale University |
| issn | 1480-9222 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | BMC |
| record_format | Article |
| series | Biological Procedures Online |
| spelling | doaj-art-a0bc8cadbcc34772a129ecacdf69b6ae2025-08-20T04:01:24ZengBMCBiological Procedures Online1480-92222025-07-0127111610.1186/s12575-025-00283-4Mitigating Tumor Recurrence through Mitochondrial Metabolism Inhibition: A Novel NIR Laser-Induced Therapeutic StrategyYao Liu0Zujun Que1Tianqi An2Zhipeng Zhang3Jianhui Tian4Clinical Oncology Center, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese MedicineClinical Oncology Center, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese MedicineClinical Oncology Center, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese MedicineClinical Oncology Center, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese MedicineClinical Oncology Center, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese MedicineAbstract Tumor recurrence driven by mitochondrial hypermetabolism remains a critical challenge in cancer therapy, as aberrant energy metabolism fuels therapeutic resistance and disease progression. We aimed to develop a multifunctional nanoplatform combining mitochondrial metabolism inhibition, photothermal therapy, and controlled chemotherapy to overcome tumor recurrence mechanisms. Biodegradable polydopamine nanoparticles (PDA-DOX-CO NPs) were engineered via molecular self-assembly, co-loading doxorubicin (DOX) and a carbon monoxide (CO) prodrug. The PDA-DOX-CO NPs demonstrated three synergistic therapeutic effects: (1) Photothermal ablation (48.38 °C tumor hyperthermia), (2) CO-mediated mitochondrial suppression, and (3) Spatiotemporally controlled DOX release. In HCT-116 tumor models, PDA-DOX-CO NPs with NIR irradiation induced 60% tumor complete ablation. Histopathological analysis confirmed significant apoptosis induction and mitochondrial morphology alterations in treated tumors. This “metabolic blockade + energy depletion + precision delivery” paradigm provides a synergistic solution to tumor recurrence, demonstrating enhanced therapeutic efficacy and biosafety through mitochondrial-targeted multimodal action.https://doi.org/10.1186/s12575-025-00283-4Antitumor therapyCO gas therapyMitochondrial metabolismPhotothermal therapyChemotherapy |
| spellingShingle | Yao Liu Zujun Que Tianqi An Zhipeng Zhang Jianhui Tian Mitigating Tumor Recurrence through Mitochondrial Metabolism Inhibition: A Novel NIR Laser-Induced Therapeutic Strategy Biological Procedures Online Antitumor therapy CO gas therapy Mitochondrial metabolism Photothermal therapy Chemotherapy |
| title | Mitigating Tumor Recurrence through Mitochondrial Metabolism Inhibition: A Novel NIR Laser-Induced Therapeutic Strategy |
| title_full | Mitigating Tumor Recurrence through Mitochondrial Metabolism Inhibition: A Novel NIR Laser-Induced Therapeutic Strategy |
| title_fullStr | Mitigating Tumor Recurrence through Mitochondrial Metabolism Inhibition: A Novel NIR Laser-Induced Therapeutic Strategy |
| title_full_unstemmed | Mitigating Tumor Recurrence through Mitochondrial Metabolism Inhibition: A Novel NIR Laser-Induced Therapeutic Strategy |
| title_short | Mitigating Tumor Recurrence through Mitochondrial Metabolism Inhibition: A Novel NIR Laser-Induced Therapeutic Strategy |
| title_sort | mitigating tumor recurrence through mitochondrial metabolism inhibition a novel nir laser induced therapeutic strategy |
| topic | Antitumor therapy CO gas therapy Mitochondrial metabolism Photothermal therapy Chemotherapy |
| url | https://doi.org/10.1186/s12575-025-00283-4 |
| work_keys_str_mv | AT yaoliu mitigatingtumorrecurrencethroughmitochondrialmetabolisminhibitionanovelnirlaserinducedtherapeuticstrategy AT zujunque mitigatingtumorrecurrencethroughmitochondrialmetabolisminhibitionanovelnirlaserinducedtherapeuticstrategy AT tianqian mitigatingtumorrecurrencethroughmitochondrialmetabolisminhibitionanovelnirlaserinducedtherapeuticstrategy AT zhipengzhang mitigatingtumorrecurrencethroughmitochondrialmetabolisminhibitionanovelnirlaserinducedtherapeuticstrategy AT jianhuitian mitigatingtumorrecurrencethroughmitochondrialmetabolisminhibitionanovelnirlaserinducedtherapeuticstrategy |